What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Can IDEAYA’s darovasertib finally redefine first-line therapy in metastatic uveal melanoma?
IDEAYA Biosciences has completed targeted full enrollment in its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib as a first-line treatment for HLA*A2-negative metastatic uveal melanoma. The company aims to support a potential accelerated approval filing in the United States based on median progression-free survival data expected in the first quarter of 2026. […]